(2S)-2-(((tert-butoxy)carbonyl)amino)pentanoic acid → methyl N-(tert-butoxycarbonyl)-L-norvalyl-L-threoninate
반응식
[C:1]([O:5][C:6]([NH:8][C@H:9]([C:13]([OH:15])=O)[CH2:10][CH2:11][CH3:12])=[O:7])([CH3:4])([CH3:3])[CH3:2].Cl.[CH2:17]([O:19][C:20](=[O:26])[C@H:21]([C@@H:23]([CH3:25])[OH:24])[NH2:22])C>>[C:1]([O:5][C:6]([NH:8][C@H:9]([C:13]([NH:22][C@H:21]([C:20]([O:19][CH3:17])=[O:26])[C@@H:23]([CH3:25])[OH:24])=[O:15])[CH2:10][CH2:11][CH3:12])=[O:7])([CH3:2])([CH3:3])[CH3:4]참가 물질
3
실험 절차
The preparation was performed in a similar manner as Example 1.001 (d) Method B from N-(tert-butoxycarbonyl)-L-norvaline (13.0 g, 59.8 mmol) and L-threonine ethyl ester hydrochloride (9.23 g, 54.4 mmol) to give methyl N-(tert-butoxycarbonyl)-L-norvalyl-L-threoninate. MS (APCI): m/z 333 (M+H).
출처 및 근거
- ORD 기록
- ord-d0aaed4f417b4af3917ef0ff3b95f332
- 출처 데이터셋
- uspto-grants-2015_03